News
Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.
FEATURED STORIES
Early-stage clinical data from our company and others point to the Wnt/β-catenin pathway as a new avenue for targeting multiple cancer types.
Biogen is growing as planned, with marketed products generating more revenue and multiple late-stage readouts expected over the next year. Building out an early-stage pipeline would be a bonus, CEO Chris Viehbacher said on a Q3 earnings call Wednesday.
BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Watching the baseball playoffs this week, I was struck by the parallels between the Los Angeles Dodgers and Eli Lilly. Both franchises spend a lot of money and always appear to come out on top.
THE LATEST
Alnylam shares dropped by a quarter on Thursday, with analysts suggesting the decline puts the RNAi specialist within range for a takeout.
Setara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals earlier this year.
After Sanofi paid $600 million in cash to acquire Dren Bio’s bispecific last year, the biotech has secured a hefty financing to fund late-stage development and commercial preparations for its lead asset.
With the commercial business performing so well, Eli Lilly is eyeing earlier business development bets to build out a longer-term pipeline.
On its third-quarter earnings investor call Thursday morning, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertension drug Winrevair that drove the pharma’s overall sales expectations to surpass expectations.
In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma raised its full-year revenue forecast.
Ono Pharma’s ONO-1110 failed five Phase 2 trials, leading to the discontinuation of development in depression and social anxiety. Work will continue for three pain indications.
Eli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.
Under the interim policy, officials do not intend to take action against sites that produce the peptides.
In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role.